Back to results
US 5,962,410 AGranted
Inhibition of eucaryotic pathogens with lytic peptides
AssigneeHelix Biomedix, Inc.
InventorsJesse M. Jaynes, Frederic M. Enright, Kenneth L. White
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeHelix Biomedix, Inc.
InventorsJesse M. Jaynes, Frederic M. Enright, Kenneth L. White
Estimating the term…
Inhibition of eucaryotic pathogens and neoplasms and stimulation of lymphocytes and fibroblasts with lytic peptides such as cecropins and sarcotoxins. Eucaryotic cells are contacted with cecropin or sarcotoxin, or a synergistic combination of cecropins or sarcotoxin with lysozyme, in an amount effective to lyse or inhibit the cells. Target cells include eucaryotic microorganisms such as protozoa, e.g. T. cruzi and P. falciparum, mammalian lymphomas and leukemias, and cells infected with intracellular pathogens such as viruses, bacteria and protozoa. Also disclosed is a method for stimulating proliferation of lymphocytes and fibroblasts by contacting such cells with an effective amount of cecropin or sarcotoxin. The methods may be in vitro or in vivo.
A method for lysing fungal cells or protozoa cells, comprising:
A method for lysing eucaryotic cells infected with intracellular pathogenic microorganisms, comprising:
A method for lysing target eucaryotic lymphoma, leukemia, or carcinoma cancer cells;
A method for treating a mammalian host diagnosed as infected with a pathogenic virus, bacteria, fungi, or protozoa;
A method for treating a mammalian host diagnosed with cancer, comprising topically or orally administering an exogenous lytic peptide;
A method for treating a mammalian host diagnosed as infected with a virus, bacteria, fungi, or protozoa;
A method for treating a mammalian host diagnosed with cancer, comprising administering in vivo an exogenous lytic peptide;
Dependencies are inferred from the claim text.